Premium
Effective Oral Administration of an Antitumorigenic Nanoformulated Titanium Complex
Author(s) -
Nahari Gilad,
Braitbard Ori,
Larush Liraz,
Hochman Jacob,
Tshuva Edit Y.
Publication year - 2021
Publication title -
chemmedchem
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.817
H-Index - 100
eISSN - 1860-7187
pISSN - 1860-7179
DOI - 10.1002/cmdc.202000384
Subject(s) - in vivo , capecitabine , pharmacology , cytotoxicity , oral administration , drug , toxicity , cancer , stomach , medicine , in vitro , chemistry , colorectal cancer , biology , biochemistry , microbiology and biotechnology
Abstract : Orally administered anticancer drugs facilitate treatment, but the acidic conditions in the stomach often challenge their availability. PhenolaTi is a Ti IV ‐based nontoxic anticancer drug with marked in‐vivo efficacy. We report that nanoformulation protects phenolaTi from decomposition in stomach‐like conditions. This is evidenced by similar NMR characteristics and similar in‐vitro cytotoxicity toward murine (CT‐26) and human (HT‐29) colon cancer cells before and after incubation of nanoformulated phenolaTi (phenolaTi‐F) at pH 2, unlike results with the unformulated form of the complex. Furthermore, administration of phenolaTi‐F in animal drinking water revealed a notable inhibition of tumor growth in Balb/c and immune‐deficient (Nude) mice inoculated with CT‐26 and HT‐29 cells, respectively. In‐vivo efficacy was at least similar to that of the corresponding intraperitoneal treatment with phenolaTi‐F and the clinically employed oral drug, capecitabine. No body weight loss or clinical signs of toxicity were evident in the phenolaTi‐F‐treated animals. These findings demonstrate a new convenient mode of cancer treatment through oral administration by safe titanium‐based drugs.